Advances in biomarkers for immunotherapy in small-cell lung cancer
Small-cell lung cancer (SCLC) is a refractory cancer with rapid growth and high aggressiveness. Extensive-stage SCLC is initially sensitive to chemotherapy; however, drug resistance and recurrence occur rapidly, resulting in a poor survival outcome due to lack of subsequently efficient therapy. The...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1490590/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850264695484710912 |
|---|---|
| author | Hui Li Hui Li Peiyan Zhao Peiyan Zhao Lin Tian Lin Tian Lin Tian Yuanhua Lu Yuanhua Lu Yuanhua Lu Xinyue Wang Xinyue Wang Xinyue Wang Wenjun Shao Wenjun Shao Wenjun Shao Ying Cheng Ying Cheng Ying Cheng |
| author_facet | Hui Li Hui Li Peiyan Zhao Peiyan Zhao Lin Tian Lin Tian Lin Tian Yuanhua Lu Yuanhua Lu Yuanhua Lu Xinyue Wang Xinyue Wang Xinyue Wang Wenjun Shao Wenjun Shao Wenjun Shao Ying Cheng Ying Cheng Ying Cheng |
| author_sort | Hui Li |
| collection | DOAJ |
| description | Small-cell lung cancer (SCLC) is a refractory cancer with rapid growth and high aggressiveness. Extensive-stage SCLC is initially sensitive to chemotherapy; however, drug resistance and recurrence occur rapidly, resulting in a poor survival outcome due to lack of subsequently efficient therapy. The emergence of immune checkpoint inhibitors (ICIs) generated a new landscape of SCLC treatment and significantly prolonged the survival of patients. However, the unselected immunotherapy restrains both beneficiary population and responsive period in SCLC compared to the other tumors. The complex tumor origin, high heterogeneity, and immunosuppressive microenvironment may disturb the value of conventional biomarkers in SCLC including programmed cell death 1 ligand 1 and tumor mutation burden. Transcriptional regulator–based subtypes of SCLC are current research hotspot, revealing that Y (I) subtype can benefit from ICIs. Additionally, molecules related to immune microenvironment, immunogenicity, epigenetics, and SCLC itself also indicated the therapeutic benefits of ICIs, becoming potential predictive biomarkers. In this review, we discussed the advances of biomarkers for prediction and prognosis of immunotherapy, promising directions in the future, and provide reference and options for precision immunotherapy and survival improvement in patients with SCLC. |
| format | Article |
| id | doaj-art-83e64f1306d04d95850529f8018bd73e |
| institution | OA Journals |
| issn | 1664-3224 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-83e64f1306d04d95850529f8018bd73e2025-08-20T01:54:38ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-12-011510.3389/fimmu.2024.14905901490590Advances in biomarkers for immunotherapy in small-cell lung cancerHui Li0Hui Li1Peiyan Zhao2Peiyan Zhao3Lin Tian4Lin Tian5Lin Tian6Yuanhua Lu7Yuanhua Lu8Yuanhua Lu9Xinyue Wang10Xinyue Wang11Xinyue Wang12Wenjun Shao13Wenjun Shao14Wenjun Shao15Ying Cheng16Ying Cheng17Ying Cheng18Medical Oncology Translational Research Lab, Jilin Cancer Hospital, Changchun, ChinaJilin Provincial Key Laboratory of Molecular Diagnostics for Lung Cancer, Jilin Cancer Hospital, Changchun, ChinaMedical Oncology Translational Research Lab, Jilin Cancer Hospital, Changchun, ChinaJilin Provincial Key Laboratory of Molecular Diagnostics for Lung Cancer, Jilin Cancer Hospital, Changchun, ChinaMedical Oncology Translational Research Lab, Jilin Cancer Hospital, Changchun, ChinaJilin Provincial Key Laboratory of Molecular Diagnostics for Lung Cancer, Jilin Cancer Hospital, Changchun, ChinaPostdoctoral Research Workstation, Jilin Cancer Hospital, Changchun, ChinaMedical Oncology Translational Research Lab, Jilin Cancer Hospital, Changchun, ChinaJilin Provincial Key Laboratory of Molecular Diagnostics for Lung Cancer, Jilin Cancer Hospital, Changchun, ChinaPostdoctoral Research Workstation, Jilin Cancer Hospital, Changchun, ChinaMedical Oncology Translational Research Lab, Jilin Cancer Hospital, Changchun, ChinaJilin Provincial Key Laboratory of Molecular Diagnostics for Lung Cancer, Jilin Cancer Hospital, Changchun, ChinaPostdoctoral Research Workstation, Jilin Cancer Hospital, Changchun, ChinaMedical Oncology Translational Research Lab, Jilin Cancer Hospital, Changchun, ChinaJilin Provincial Key Laboratory of Molecular Diagnostics for Lung Cancer, Jilin Cancer Hospital, Changchun, ChinaPostdoctoral Research Workstation, Jilin Cancer Hospital, Changchun, ChinaMedical Oncology Translational Research Lab, Jilin Cancer Hospital, Changchun, ChinaJilin Provincial Key Laboratory of Molecular Diagnostics for Lung Cancer, Jilin Cancer Hospital, Changchun, ChinaDepartment of Thoracic Oncology, Jilin Cancer Hospital, Changchun, ChinaSmall-cell lung cancer (SCLC) is a refractory cancer with rapid growth and high aggressiveness. Extensive-stage SCLC is initially sensitive to chemotherapy; however, drug resistance and recurrence occur rapidly, resulting in a poor survival outcome due to lack of subsequently efficient therapy. The emergence of immune checkpoint inhibitors (ICIs) generated a new landscape of SCLC treatment and significantly prolonged the survival of patients. However, the unselected immunotherapy restrains both beneficiary population and responsive period in SCLC compared to the other tumors. The complex tumor origin, high heterogeneity, and immunosuppressive microenvironment may disturb the value of conventional biomarkers in SCLC including programmed cell death 1 ligand 1 and tumor mutation burden. Transcriptional regulator–based subtypes of SCLC are current research hotspot, revealing that Y (I) subtype can benefit from ICIs. Additionally, molecules related to immune microenvironment, immunogenicity, epigenetics, and SCLC itself also indicated the therapeutic benefits of ICIs, becoming potential predictive biomarkers. In this review, we discussed the advances of biomarkers for prediction and prognosis of immunotherapy, promising directions in the future, and provide reference and options for precision immunotherapy and survival improvement in patients with SCLC.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1490590/fullsmall-cell lung cancerimmunotherapybiomarkerresearch advancespredictiveprognosis |
| spellingShingle | Hui Li Hui Li Peiyan Zhao Peiyan Zhao Lin Tian Lin Tian Lin Tian Yuanhua Lu Yuanhua Lu Yuanhua Lu Xinyue Wang Xinyue Wang Xinyue Wang Wenjun Shao Wenjun Shao Wenjun Shao Ying Cheng Ying Cheng Ying Cheng Advances in biomarkers for immunotherapy in small-cell lung cancer Frontiers in Immunology small-cell lung cancer immunotherapy biomarker research advances predictive prognosis |
| title | Advances in biomarkers for immunotherapy in small-cell lung cancer |
| title_full | Advances in biomarkers for immunotherapy in small-cell lung cancer |
| title_fullStr | Advances in biomarkers for immunotherapy in small-cell lung cancer |
| title_full_unstemmed | Advances in biomarkers for immunotherapy in small-cell lung cancer |
| title_short | Advances in biomarkers for immunotherapy in small-cell lung cancer |
| title_sort | advances in biomarkers for immunotherapy in small cell lung cancer |
| topic | small-cell lung cancer immunotherapy biomarker research advances predictive prognosis |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1490590/full |
| work_keys_str_mv | AT huili advancesinbiomarkersforimmunotherapyinsmallcelllungcancer AT huili advancesinbiomarkersforimmunotherapyinsmallcelllungcancer AT peiyanzhao advancesinbiomarkersforimmunotherapyinsmallcelllungcancer AT peiyanzhao advancesinbiomarkersforimmunotherapyinsmallcelllungcancer AT lintian advancesinbiomarkersforimmunotherapyinsmallcelllungcancer AT lintian advancesinbiomarkersforimmunotherapyinsmallcelllungcancer AT lintian advancesinbiomarkersforimmunotherapyinsmallcelllungcancer AT yuanhualu advancesinbiomarkersforimmunotherapyinsmallcelllungcancer AT yuanhualu advancesinbiomarkersforimmunotherapyinsmallcelllungcancer AT yuanhualu advancesinbiomarkersforimmunotherapyinsmallcelllungcancer AT xinyuewang advancesinbiomarkersforimmunotherapyinsmallcelllungcancer AT xinyuewang advancesinbiomarkersforimmunotherapyinsmallcelllungcancer AT xinyuewang advancesinbiomarkersforimmunotherapyinsmallcelllungcancer AT wenjunshao advancesinbiomarkersforimmunotherapyinsmallcelllungcancer AT wenjunshao advancesinbiomarkersforimmunotherapyinsmallcelllungcancer AT wenjunshao advancesinbiomarkersforimmunotherapyinsmallcelllungcancer AT yingcheng advancesinbiomarkersforimmunotherapyinsmallcelllungcancer AT yingcheng advancesinbiomarkersforimmunotherapyinsmallcelllungcancer AT yingcheng advancesinbiomarkersforimmunotherapyinsmallcelllungcancer |